Clinical Trial Update: A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial evaluating AEB071 in patients with moderate to severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• AEB071 (sotrastaurin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate and Severe Plaque Psoriasis | Phase 2 | Status: COMPLETED